These treatments, though prohibited, will not require such patients to be discontinued from the study. Their efficacy and safety outcomes will be included in the intent-to-treat (ITT) and safety analyses, respectively. The data from patients who received prohibited treatment/medications will be considered major protocol violations and excluded from the per-protocol (PP) analyses.